BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Erdafitinib (Balversa) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Erdafitinib (Balversa)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04963153-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Erdafitinib (Balversa): Phase 1 readout est. (NCT04963153)
DESCRIPTION:Erdafitinib (Balversa)\, phase 1\, Urothelial Carcinoma.\nStudy
 : Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bla
 dder Cancer After Treatment With Chemotherapy and Immunotherapy\nEstimated
  primary completion: 1 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/erdafitinib-balversa#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04963153
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04917809-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Erdafitinib (Balversa): Phase 2 readout est. (NCT04917809)
DESCRIPTION:Erdafitinib (Balversa)\, phase 2.\nStudy: A Study of Oral Erdaf
 itinib in People With Recurrent Non-Invasive Bladder Cancer\nEstimated pri
 mary completion: August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/erdafitinib-balversa#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04917809
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Erdafitinib (Balversa): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Erdafitinib (Balversa)\, phase 2.\nStudy: The Drug Rediscovery 
 Protocol (DRUP Trial)\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/erdafitinib-balversa#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05859334-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271023
DTEND;VALUE=DATE:20271024
SUMMARY:Erdafitinib (Balversa): Phase 2 readout est. (NCT05859334)
DESCRIPTION:Erdafitinib (Balversa)\, phase 2.\nStudy: Testing the Anti-canc
 er Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Fol
 lowing Treatment\nEstimated primary completion: 23 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05859334
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Erdafitinib (Balversa): Phase 2 readout est. (NCT02465060)
DESCRIPTION:Erdafitinib (Balversa)\, phase 2.\nStudy: Targeted Therapy Dire
 cted by Genetic Testing in Treating Patients With Advanced Refractory Soli
 d Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05316155-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Erdafitinib (Balversa): Phase 1/2 readout est. (NCT05316155)
DESCRIPTION:Erdafitinib (Balversa)\, phase 1/2.\nStudy: Study of Erdafitini
 b Intravesical Delivery System for Localized Bladder Cancer\nEstimated pri
 mary completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/erdafitinib-balversa#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05316155
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-2255@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Erdafitinib (Balversa): Phase 1 readout est. (NCT06204614)
DESCRIPTION:Erdafitinib (Balversa)\, phase 1\, Urothelial Carcinoma.\nStudy
 : Drug Screening Using IMD in Bladder Cancer\nEstimated primary completion
 : 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/erdafi
 tinib-balversa#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06204614
URL:https://assetmemo.bio/drug/erdafitinib-balversa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
